Overview

Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation

Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label Phase Ib clinical study with the primary objective of evaluating the safety and tolerability of multiple subcutaneous injections of SHR-2004 injection in patients with atrial fibrillation, and the secondary objective is to evaluate its pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity characteristics.
Phase:
PHASE1
Details
Lead Sponsor:
Beijing Suncadia Pharmaceuticals Co., Ltd